Centering discussion on several patient scenarios, expert panelists review recent clinical data and consider how it has impacted their management of patients with small cell lung cancer (SCLC).
EP. 2: Impact of Disease Staging on Prognosis and Treatment in SCLC
Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.
EP. 3: Evolving Role of Biomarkers in SCLC
Faculty discuss the evolving role of molecular markers in small-cell lung cancer and the need for future research to identify improved biomarkers for targeted treatment options.
EP. 4: Patient Scenario 1: Newly Diagnosed ES-SCLC With Presence of Hepatic and Brain Metastases
A panel of expert oncologists present the case of a 68-year-old man with newly diagnosed, extensive stage small-cell lung cancer and brain metastases, who is treated with carboplatin, etoposide, and durvalumab, and provide their initial impressions.
EP. 5: Expert Insights on First-line Treatment Strategies in SCLC
An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection.
EP. 6: CASPIAN: Long-Term Follow-up Data and Potential Predictors for Treatment Outcomes
Expert oncologists discuss long-term data updates from the CASPIAN trial and the associated implications on clinical practice.
EP. 7: Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC
Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.
EP. 8: ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC
Faculty discuss potential treatment approaches for limited stage small-cell lung cancer currently under investigation in the ADRIATIC and other ongoing trials.
Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.
EP. 10: Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC
Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer.
EP. 11: Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy
A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.
EP. 12: Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond
Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.
EP. 13: LAGOON and IMFORTE Trials: Data Updates and Expert Insights
A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.
EP. 14: 2L Dosing Considerations and Management Strategies for SCLC
Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.
EP. 15: Novel Treatment Approaches for SCLC and Future Perspectives
A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.